Cytek Biosciences (NasdaqGS:CTKB) - Share price, News & Analysis

CTKB fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	2/6
Financial Health	6/6
Dividends	0/6

CTKB Overview

Rewards

Revenue is forecast to grow 23.16% per year

Became profitable this year

Risk Analysis

Volatile share price over the past 3 months

Cytek Biosciences Competitors

Thermo Fisher Scientific

NYSE:TMO

US$238.7b

Illumina

NasdaqGS:ILMN

US$63.8b

Agilent Technologies

NYSE:A

US$52.2b

Bio-Rad Laboratories

NYSE:BIO

US$23.4b

Price History & Performance

Summary of all time highs, changes and price drops for Cytek Biosciences
Historical stock prices
Current Share Price	US$24.40
52 Week High	US$17.40
52 Week Low	US$28.70
Beta	0
1 Month Change	5.86%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	30.06%

Shareholder Returns

	CTKB	US Life Sciences	US Market
7D	-12.4%	2.3%	-1.7%
1Y	n/a	58.3%	36.2%

Return vs Industry: Insufficient data to determine how CTKB performed against the US Life Sciences industry.

Return vs Market: Insufficient data to determine how CTKB performed against the US Market.

Price Volatility

Is CTKB's price volatile compared to industry and market?
CTKB volatility
CTKB Beta	0
Industry Beta	0.97
Market Beta	1

Stable Share Price: CTKB is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: Insufficient data to determine CTKB's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2014	429	Wenbin Jiang	https://cytekbio.com

Cytek Biosciences, Inc. engages in the manufacture and sale of cell analysis solutions for clinical and biomedical research in the fields of drug discovery, genomics, immuno-oncology, immuno-profiling, infectious diseases, inflammatory diseases, and multi-site standardization applications. Its instruments include the Aurora and Northern Lights systems, which are flow cytometers to deliver cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. The company also offers cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments.

Cytek Biosciences Fundamentals Summary

How do Cytek Biosciences's earnings and revenue compare to its market cap?
CTKB fundamental statistics
Market Cap	US$3.20b
Earnings (TTM)	US$2.02m
Revenue (TTM)	US$110.40m

1.6kx

P/E Ratio

29.9x

P/S Ratio

Is CTKB overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
CTKB income statement (TTM)
Revenue	US$110.40m
Cost of Revenue	US$41.10m
Gross Profit	US$69.30m
Expenses	US$67.28m
Earnings	US$2.02m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	0.066
Gross Margin	62.77%
Net Profit Margin	1.83%
Debt/Equity Ratio	0.0%

How did CTKB perform over the long term?

See historical performance and comparison

Valuation

Is Cytek Biosciences undervalued compared to its fair value and its price relative to the market?

1634.29x

Price to Earnings (PE) ratio

Share Price vs. Fair Value

Below Fair Value: CTKB ($24.4) is trading above our estimate of fair value ($2.25)

Significantly Below Fair Value: CTKB is trading above our estimate of fair value.

Price To Earnings Ratio

PE vs Industry: CTKB is poor value based on its PE Ratio (1634.3x) compared to the US Life Sciences industry average (52.2x).

PE vs Market: CTKB is poor value based on its PE Ratio (1634.3x) compared to the US market (17.7x).

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CTKB's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: CTKB has negative assets, so we can't compare its PB Ratio to the US Life Sciences industry average.

Future Growth

How is Cytek Biosciences forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

23.2%

Forecasted annual revenue growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if CTKB's forecast earnings growth is above the savings rate (2%).

Earnings vs Market: Insufficient data to determine if CTKB's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: CTKB's revenue (23.2% per year) is forecast to grow faster than the US market (9.8% per year).

High Growth Revenue: CTKB's revenue (23.2% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: CTKB's Return on Equity is forecast to be low in 3 years time (4.8%).

Past Performance

How has Cytek Biosciences performed over the past 5 years?

46.7%

Last years revenue growth

Earnings and Revenue History

Quality Earnings: CTKB has high quality earnings.

Growing Profit Margin: CTKB became profitable in the past.

Past Earnings Growth Analysis

Earnings Trend: Unable to establish if CTKB's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.

Accelerating Growth: Unable to compare CTKB's past year earnings growth to its 5-year average as it has been trading publicly for less than 3 years.

Earnings vs Industry: CTKB has become profitable in the last year, making it difficult to compare its past year earnings growth to the Life Sciences industry (56.9%).

Return on Equity

High ROE: CTKB's Return on Equity (8.1%) is considered low.

Financial Health

How is Cytek Biosciences's financial position?

Financial Position Analysis

Short Term Liabilities: CTKB's short term assets ($216.9M) exceed its short term liabilities ($28.2M).

Long Term Liabilities: CTKB's short term assets ($216.9M) exceed its long term liabilities ($18.8M).

Debt to Equity History and Analysis

Debt Level: CTKB is debt free.

Reducing Debt: CTKB had no debt 5 years ago.

Debt Coverage: CTKB has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: CTKB has no debt, therefore coverage of interest payments is not a concern.

Balance Sheet

Dividend

What is Cytek Biosciences's current dividend yield, its reliability and sustainability?

Dividend Yield vs Market

Notable Dividend: Unable to evaluate CTKB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CTKB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CTKB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CTKB's dividend payments have been increasing.

Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CTKB's dividend in 3 years as they are not forecast to pay a notable one for the US market.

Next Steps

Explore strong dividend paying companies in the Pharmaceuticals & Biotech industry.

Management

How experienced are the management team and are they aligned to shareholders interests?

1.7yrs

Average management tenure

CEO

Wenbin Jiang (57 yo)

6.75yrs

Tenure

US$422,221

Compensation

Dr. Wenbin Jiang, Ph D., is co-founder and President of Cytek Biosciences, Inc and has been its Chief Executive Officer and Director since December 2014. Dr. Jiang is a seasoned entrepreneur and inventor....

CEO Compensation Analysis

Compensation vs Market: Wenbin's total compensation ($USD422.22K) is below average for companies of similar size in the US market ($USD5.28M).

Compensation vs Earnings: Insufficient data to compare Wenbin's compensation with company performance.

Leadership Team

Experienced Management: CTKB's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.

Board Members

Experienced Board: CTKB's board of directors are considered experienced (3.1 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: CTKB insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: CTKB only recently listed within the past 12 months.

Data	Last Updated (UTC time)
Company Analysis	2021/09/23 23:08
End of Day Share Price	2021/09/23 00:00
Earnings	2021/06/30
Annual Earnings	2020/12/31

Market Cap

7D

1Y

Updated

Data